Evidence map›Paper›PMID 36672786›Full record

ArticleGenes2022

Melatonin and MitoEbselen-2 Are Radioprotective Agents to Mitochondria.

Tsutomu Shimura, Rina Shiga, Megumi Sasatani, Kenji Kamiya, Akira Ushiyama

Open access · goldAbstract read
In one paragraph

Article in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. The Chemotherapy Medication ofCancer management and research · 2025
    Article
  5. Mitochondrial Signaling Pathways Associated with DNA Damage Responses.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Tsutomu ShimuraDepartment of Environmental Health, National Institute of Public Health, Wako 351-0197, Japan.ORCID 0000-0002-2418-2991
Rina ShigaMeiji Pharmaceutical University, Kiyose 204-8588, Japan.
Megumi SasataniDepartment of Experimental Oncology, Research Center for Radiation Genome Medicine, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima 734-8553, Japan.ORCID 0000-0002-1219-1014
Kenji KamiyaDepartment of Experimental Oncology, Research Center for Radiation Genome Medicine, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima 734-8553, Japan.
Akira UshiyamaDepartment of Environmental Health, National Institute of Public Health, Wako 351-0197, Japan.
Hiroshima University · JPNational Institute of Public Health · JPMeiji Pharmaceutical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitochondria are responsible for controlling cell death during the early stages of radiation exposure, but their perturbations are associated with late effects of radiation-related carcinogenesis. Therefore, it is important to protect mitochondria to mitigate the harmful effects of radiation throughout life. The glutathione peroxidase (GPx) enzyme is essential for the maintenance of mitochondrial-derived reactive oxygen species (ROS) levels. However, radiation inactivates the GPx, resulting in metabolic oxidative stress and prolonged cell injury in irradiated normal human fibroblasts. Here, we used the GPx activator

Indexed as

MelatoninRadiation-Protective AgentsAntioxidantsHumansMitochondriaReactive Oxygen SpeciesAntioxidantsMelatoninRadiation-Protective AgentsReactive Oxygen Speciesglutathione peroxidasemelatoninmitochondriaMitoEbselen-2radiation protection

Identifiers

PMID36672786
PMCPMC9858905
OpenAlexW4313245686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.